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ABSTRACT
Background: Low-molecular-weight heparin (LMWH)
is the drug of choice to prevent venous thrombosis in
pregnancy, but the optimal dose for prevention while
avoiding bleeding is unclear. This study investigated
whether therapeutic doses of LMWH increase the
incidence of postpartum haemorrhage (PPH) in
a retrospective controlled cohort.
Methods: All pregnant women who received
therapeutic doses of LMWH between 1995 and 2008
were identiﬁed in the Academic Medical Center,
Amsterdam, The Netherlands. The controls were
women registered for antenatal care in the same
hospital who did not use LMWH during pregnancy,
matched by random electronic selection for age, parity
and delivery date to LMWH users. The incidence of
PPH (blood loss >500 ml), severe PPH (blood loss
>1000 ml) and median blood loss were compared in
two cohorts of LMWH users and non-users.
Results: The incidence of PPH was 18% in LMWH
users (N¼95) and 22% in non-users (N¼524) (RR
0.8; 95% CI 0.5 to 1.4). The incidence of severe PPH
was 6% in both groups (RR 1.2; 0.5 to 2.9). The
median amount of blood loss differed only in normal
vaginal deliveries. It was 200 ml in LMWH users and
300 ml in non-users (difference  100 ml; 95% CI
 156 to  44).
Conclusion: Therapeutic doses of LMWH in
pregnancy were observed not to be associated with
a clinically meaningful increase in the incidence of PPH
or severe PPH in women delivered in this hospital,
although this observation may be confounded by the
differential use of strategies to prevent bleeding. A
randomised controlled trial is necessary to provide
a deﬁnite answer about the optimal dose of LMWH in
pregnancy.
Low-molecular-weight heparin (LMWH) is
the drug of choice in pregnant women
requiring prophylaxis or treatment for
venous thrombosis. However, the optimal
dose with respect to efﬁcacy and safety is
uncertain.
1 LMWH has the disadvantage that
its anticoagulant effect can only be partly
antagonised. This is of particular importance
with respect to its use in high doses and raises
concerns about an increased risk of bleeding,
most notably postpartum haemorrhage
(PPH), when used in pregnant women.
PPH is deﬁned by the WHO as postpartum
blood loss in excess of 500 ml.
2 However, as
other deﬁnitions have been suggested,
3 we
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ARTICLE SUMMARY
Article focus
- To compare the incidence of PPH (ie, blood loss
>500 ml in the ﬁrst 24 h of delivery) in two
cohorts of pregnant women who were treated
with therapeutic doses of LMWH and those who
were not.
- To compare the incidence of severe PPH (blood
loss >1000 ml) in two cohorts of pregnant
women who were treated with therapeutic
doses of LMWH and those who were not.
- To compare the median blood loss in two
cohorts of pregnant women who were treated
with therapeutic doses of LMWH and those who
were not.
Key message
- Therapeutic doses of LMWH in pregnancy were
not associated with a clinically meaningful
increase in the incidence of PPH (RR 0.8; 95%
CI 0.5 to 1.4) or severe PPH (RR 1.2; 0.5 to 2.9)
in women delivered in our hospital.
- The median amount of blood loss differed only in
normal vaginal deliveries. It was lower in LMWH
users (200 ml) than in non-users (300 ml)
(difference  100 ml; 95% CI  156 to  44).
Strength and limitation of this study
- This is the largest cohort of pregnancies treated
with high doses of LMWH.
- Although this was a controlled cohort study, it is
likely that strategies to decrease the risk of PPH
differed between women who were treated with
LMWH and controls.
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PPH has an incidence of 19% in nulliparous deliveries in
The Netherlands.
4 The diagnosis encompasses excessive
blood loss from the uterus, cervix, vagina and perineum.
The commonest cause of primary PPH (PPH <24 h
following delivery) is uterine atony.
5 In order to limit the
risk of PPH, current guidelines recommend the discon-
tinuation of LMWH 12e24 h before delivery.
16However,
as labour can commence spontaneously, timely discon-
tinuation cannot be guaranteed. The risk of PPH associ-
ated with the use of LMWH has been assessed in several
studies.
37 e13 These studies either included a small or an
unknown number of women treated with therapeutic
doses of LMWH
37 e10 or they lacked a control group of
women who did not use LMWH.
79 e11 13 Only two studies
report the bleeding risk associated with antepartum
therapeutic doses of LMWH: a prospective multicentre
survey in the UK and Ireland and a systematic review of
studies about LMWH use in pregnancy.
11 13 Blood loss
more than 500 ml was observed in six of 126 (4.8%) and
three of 174 (1.7%) women who were treated with ther-
apeutic doses of LMWH in the two studies, respectively.
On the other hand, signiﬁcant failure rates have been
observed despite prophylaxis with low-dose LMWH in
pregnancy.
14e16 In our hospital, pregnant women who we
judge to require anticoagulant prophylaxis are treated
with therapeutic doses of LMWH. This protocol was
based on a systematic review that we performed in 1998.
14
In this review of several cohorts of women, recurrent
venous thromboembolism (VTE) occurred in 2.0% (3/
149) of pregnant women, all of whom were treated with
prophylactic or intermediate doses of LMWH. Similar
ﬁndings were reported in another large cohort study in
which seven out of eight recurrent episodes of VTE
occurred in women on prophylactic or intermediate
doses of enoxaparin.
15
We performed a controlled cohort study in our
hospital to assess the risk of PPH associated with thera-
peutic doses of LMWH in pregnant women.
MATERIALS AND METHODS
Identiﬁcation of study cohorts
By hospital protocol, anti-Xa levels were measured at
1-month intervals in women who were treated with
therapeutic doses of LMWH or heparinoid during
pregnancy. Our study cohort was thus identiﬁed by the
collection of hospital ID numbers in whom anti-Xa
measurements were performed between mid-August 1995
and mid-February 2008. We reviewed charts to assess
whether the anti-Xa measurements were performed
during pregnancy. Inclusion criteria were: therapeutic
doses of LMWH, pregnancy duration of at least 25 weeks’
gestation and delivery in the Academic Medical Center
(AMC).
The control cohort consisted of women who had been
registered for antenatal care in the AMC before 24 weeks’
gestational age, delivered in the AMC and did not use
LMWH during their pregnancy. Women treated with
LMWH and controls were matched by random electronic
selection for age (62 years), parity (nulliparous or
multiparous) and date of delivery (61 year) in a 1:6 ratio.
This study was approved by the Medical Ethics Committee
of the Academic Medical Center in Amsterdam.
Intervention
The hospital protocol was to base LMWH doses on body
weight before pregnancy, in which the therapeutic dose
of LMWH was prescribed according to the manufacturer
(table 1).
All women were seen at the outpatient clinic of the
Department of Vascular Medicine at regular intervals in
which measurements of anti-Xa levels were performed.
Dose adjustments were only done if peak anti-Xa activity
was lower than 0.4 or higher than 1.2 anti-Xa units on
repeated occasions. A multidisciplinary team of obste-
tricians and vascular medicine experts discussed patients
at regular intervals. Women were advised to discontinue
LMWH as soon as either contractions started,
membranes ruptured or to administer the last injection
the morning before the day that induction of labour or
a caesarean section was planned. Women were also
informed that epidural or spinal anaesthesia was
contraindicated within 24 h after the last dose of LMWH.
Management of postpartum haemorrhage was
performed at the attending obstetrician’s discretion.
Outcomes
The primary outcomes were PPH and severe PPH
deﬁned as the amount of blood loss estimated by the
attending obstetrician or midwife of more than 500 ml
and more than 1000 ml, respectively, within 24 h of
Table 1 Types of LMWH administered and the median and range of the doses per day
LMWH type N Median* Range Weight range
Enoxaparin, mg 16 120 60e200 53e116
Dalteparin, IU anti-Xa 9 15000 10000e20000 64e115
Nadroparin, IU anti-Xa 64
<75 kg 33 11400 11400e15200 48e74
$75 kg 31 15200 11400e20900 75e117
Danaparoid, IU anti-Xa 3 4000 3000e4500 55e66
Tinzaparin, IU anti-Xa 3 18000 14000e28000 75e82
*Doses are presented in milligrams for enoxaparin and IU for other low-molecular-weight heparins (LMWH).
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amount of blood loss in millilitres, blood transfusions in
the ﬁrst week postpartum, and recurrent VTE.
Statistical analysis
We calculated the incidence of PPH and severe PPH for
LMWH users and non-users. Relative risks (RR) of PPH
and severe PPH and their 95% CI in pregnant women
treated with therapeutic doses of LMWH compared with
non-users were calculated. Non-normally distributed
data are presented as medians. We calculated the
median blood loss difference between two cohorts of
women and its 95% CI. Furthermore, we compared the
median blood loss of both groups in strata of a priori
deﬁned other risk factors, if known (ie, type of vaginal
delivery (normal vs assisted) or caesarean section (elec-
tive vs emergency), perineal laceration degree and
ethnicity) to investigate their interaction with LMWH on
the incidence of PPH. Blood transfusion in the ﬁrst 24 h
of delivery was compared between two groups of the
study using the c
2 test.
RESULTS
We identiﬁed 95 women who used therapeutic doses of
LMWH during pregnancy for various indications (see
ﬁgure 1 for case selection) and 524 women as a control
cohort who did not use LMWH in their pregnancy.
Baseline characteristics of the study groups are shown in
table 2. Median gestational age (range) was 39 weeks
(26e44) in LMWH users and 39 weeks (25e43) in non-
users. In both cohorts, almost 93% of vaginal deliveries
proceeded spontaneously (normal vaginal delivery) and
7% needed assistance. Almost a quarter (23%) of the
women treated with LMWH delivered by caesarean
section; half of these were elective, ie, planned before
the onset of labour. In the control cohort 10% of the
women underwent caesarean sections, most were emer-
gency caesarean sections (90%).
Table 3 demonstrates the outcomes of the study, some
stratiﬁed for types and subtypes of delivery. PPH
occurred in 18% of women who used therapeutic doses
of LMWH and in 22% of controls (RR for PPH 0.8; 95%
CI 0.5 to 1.4). The incidence of severe PPH (6%) was the
same in the two groups of LMWH users and non-users
(RR for severe PPH 1.2; 95% CI 0.5 to 2.9). The risk of
PPH and severe PPH after vaginal or caesarean section
delivery was not statistically signiﬁcantly different
between the two groups of women.
Median blood loss after vaginal delivery was 250 ml
(range 50e4000) and 300 ml (20e3600) ml in LMWH
users and non-users, respectively (median difference
 50; 95% CI  102 to 2). After caesarean section, it was
425 ml (200e2000) in LMWH users and 400 ml
(100e2000) in non-users (25;  153 to 203). Median
blood loss stratiﬁed for subtypes of delivery differed
between LMWH users and non-users only after
normal vaginal deliveries (200 ml (range 50e4000) and
300 ml (20e3600)) in LMWH users and non-users,
respectively.
Median blood loss did not differ between groups after
stratiﬁcation for ethnicity and perineal laceration degree
(data not shown).
Blood transfusion was given, at the discretion of the
attending obstetrician, in 5% of LMWH users and 3% of
non-users after delivery (OR 1.6; 95% CI 0.6 to 4.3).
In terms of efﬁcacy, recurrent VTE was suspected in
one woman (1.2%; 95% CI 0.6 to 5.8) despite the use of
therapeutic doses of LMWH. However, a recurrent
episode was not conﬁrmed as ventilation/perfusion
scintigraphy revealed a perfusion defect on the same
localisation as the previous pulmonary embolism.
DISCUSSION
We observed that the incidence of severe bleeding
during delivery was not increased by using therapeutic
doses of LMWH during pregnancy, although a non-
statistically signiﬁcant increase in the risk of severe PPH
was noticed.
Similar to our ﬁnding, a previous study reported no
difference in the risk of PPH (5.7%) in women who
delivered vaginally and used LMWH (doses not speci-
ﬁed) and those who did not use LMWH (OR 1.0; 95% CI
0.2 to 4.7).
3 However, the absolute risk of PPH in our
study cohorts (12% in LMWH users and 21% in non-
LMWH users) was relatively higher. Although the inci-
dence of PPH in our control group appears to be higher
compared with other studies that assessed PPH in the
general population,
17e19 a previously performed popu-
lation-based cohort study in The Netherlands also
observed an incidence of PPH of 19%.
4 An explanation
could be the difference in blood loss estimation and in
treatment regimens. In The Netherlands, an active
management in the third stage of delivery (such as
prophylactic administration of oxytocics, immediate
cord clamping or controlled cord traction) is not
Figure 1 Inclusion ﬂowchart of women treated with low-
molecular-weight heparin.
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Low-molecular-weight heparin and postpartum haemorrhageTable 2 Baseline characteristics of the two study groups
Women who used
therapeutic dose
of LMWH (N[95)
Women who did not
use LMWH (N[524)
Age, years median (range) 32 (21e43) 31 (18e44)
Ethnicity N (%)
Caucasian 67 (70) 264 (50)
African 14 (15) 167 (32)
Others/unknown* 14 (15) 93 (18)
Gestational age, weeks median (range) 39 (26e44) 39 (25e43)
Delivery route
Vaginal N (% of all women) 73 (77) 472 (90)
Normal delivery (% of vaginal deliveries) 67 (92) 437 (93)
Assisted delivery (% of vaginal deliveries) 6 (8) 35 (7)
Caesarean section N (% of all women) 22 (23) 52 (10)
Primary caesarean section (% of caesarean sections) 11 (50) 5 (10)
Emergency caesarean section (% of caesarean sections) 11 (50) 47 (90)
Perineal laceration degree N (% of vaginal deliveries)
1st degree 7 (10) 43 (9)
2nd degree, episiotomy 12 (16) 59 (12)
2nd degree, spontaneous rupture 24 (33) 100 (22)
3rd degree 0 (0) 7 (1)
No laceration 29 (40) 263 (56)
Unknown 1 (1) e
Birth weight, grams median (range) 3150 (365e4290) 3235 (555e5035)
Indication for LMWH administration N (% of all women)
History of VTE 15 (16)
History of VTE and thrombophilia 52 (55)
Current VTEy 11 (12)
Current VTEy and thrombophilia 2 (2)
Recurrent thrombophlebitis and thrombophilia 1 (1)
Antiphospholipid syndrome 4 (4)
Pre-eclampsia 1 (1)
Prosthetic heart valve 7 (7)
Prosthetic heart valve + current heart thrombosis 1 (1)
Current CVA 1 (1)
*Data on ethnicity for two cases were missing.
yVTE during current pregnancy.
CVA, cerebrovascular accident; LMWH, low-molecular-weight heparin; VTE, venous thromboembolism.
Table 3 Incidence of PPH, severe PPH and median (range) of blood loss stratiﬁed for types of deliveries and blood transfusion
rate in two groups of the study
Women who used
therapeutic doses
of LMWH (N[95)
Women who did not
use LMWH (N[524) RR
Median
difference
95% CI of RR or
median difference
PPH events N (%) 17 (18) 113 (22) 0.8 0.5 to 1.4
Vaginal delivery 9 (12) 100 (21) 0.5 0.3 to 1.1
Caesarean section 8 (36) 13 (25) 1.7 0.6 to 5.0
Severe PPH events N (%) 6 (6) 29 (6) 1.2 e 0.5 to 2.9
Vaginal delivery 4 (5) 27 (6) 0.9 0.3 to 2.8
Caesarean section 2 (9) 2 (4) 2.5 0.3 to 18.9
Blood loss median (range)
Vaginal delivery 250 (50e4000) 300 (20e3600) ee 50 e102 to 2
Normal vaginal delivery 200 (50e4000) 300 (20e3600) ee 100 e156 to e44
Assisted vaginal delivery 350 (250e550) 400 (100e2500) ee 50 e217 to 117
Caesarean section 425 (200e2000) 400 (100e2000) e 25 e153 to 203
Primary caesarean section 450 (200e1200) 200 (100e400) e 250 e15 to 515
Emergency caesarean section 400 (200e2000) 400 (100e2000) e 0 e225 to 225
Blood transfusion N (%) 5 (5) 18 (3) 1.6 e 0.6 to 4.3
LMWH, low-molecular-weight heparin; PPH, postpartum haemorrhage.
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the third stage of delivery have been shown to reduce the
amount of blood loss.
20 Therefore, we hypothesise that
withholding oxytocics might have led to a higher inci-
dence of PPH in our control cohort, whereas this was not
observed in the treated women because LMWH use
warranted an active management of the third stage of
delivery according to the hospital protocol. Further-
more, as our hospital is a tertiary referral centre, the
observed high incidence of blood loss more than 500 ml
in the control cohort may be explained by comorbidities
that increase the risk of a complicated delivery.
For caesarian section, the incidence of severe PPH may
be more relevant to evaluate because blood loss between
500 and 1000 ml is not considered uncommon during
surgery. Severe PPH risk was 2.5 times higher (95% CI
0.3 to 18.9) in women who used LMWH compared with
those who did not, although the certainty of this esti-
mate is limited by the small number of individuals in this
stratum. In another study in which the doses of the
administered LMWH was not speciﬁed, the risk of severe
PPH for LMWH users (5%) in caesarean sections was
surprisingly stated as half of the controls (12.5%) (OR
0.4; 95% CI 0.04 to 3.4).
3
Although this is the largest cohort of pregnancies
treated with high doses of LMWH, its power to calculate
the risk of PPH is limited and is at most 44% in calcu-
lating the RR of PPH in vaginal deliveries. Therefore, we
compared the median of blood loss between cohorts of
LMWH users and non-users considering that the median
is less sensitive to outliers. The only difference in median
blood loss was found in the subgroup of normal vaginal
deliveries in which it was lower in the LMWH users.
Some issues warrant comment. First, although this was
a controlled cohort study, it is likely that strategies to
decrease the risk of PPH differed between women who
were treated with LMWH and controls. Given the
observational study design, our study does not exclude
an increased risk of PPH by the use of therapeutic
LMWH if similar obstetric measures are taken. Second,
we have not measured anti-Xa levels shortly before
delivery, as this was not part of the hospital protocol.
However, the advice given to all women reﬂects a real-life
situation (ie, to discontinue LMWH when contractions
started, membranes ruptured or the evening before the
planned induction of labour or caesarean section).
Furthermore, evidence about the association between
this duration and the risk of PPH is conﬂicting.
8 92 1
Third, blood loss was estimated rather than measured,
which may have led to higher estimates.
22 This was done
similarly in women treated and untreated with LMWH. If
anything, it is more likely that blood loss would be
overestimated rather than underestimated in women
who used LMWH than in women without LMWH.
In conclusion, we observed that therapeutic doses of
LMWH administered in pregnancy was not associated
with clinically meaningful increase in the incidence of
PPH or severe PPH in women who delivered in our
hospital. Although this observation may be confounded
by the differential use of strategies to prevent bleeding, it
is unlikely that LMWH levels in blood at the time of
delivery can cause PPH knowing the routine recom-
mendations to stop the injections when signs of labour
start. A randomised controlled trial to assess the safety of
therapeutic doses of LMWH to prevent VTE in pregnant
women is necessary to provide a deﬁnite answer about
the optimal dose of LMWH in this population.
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